Welcome to our dedicated page for Biomea Fusion SEC filings (Ticker: BMEA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Access the complete archive of SEC filings for Biomea Fusion Inc (NASDAQ: BMEA), a clinical-stage biopharmaceutical company developing oral therapies for diabetes and obesity. SEC filings provide the most authoritative source of information about the company's financial condition, clinical progress, risk factors, and business strategy. These regulatory disclosures are essential for conducting thorough due diligence on BMEA stock.
Key filing types include Form 10-K annual reports, which offer detailed analysis of the company's business operations, clinical trial results, intellectual property portfolio, competitive landscape, and audited financial statements. Form 10-Q quarterly reports provide updates on trial enrollment, cash burn rate, research and development expenses, and material developments that occurred during the quarter. Form 8-K current reports disclose material events such as clinical trial results, financing activities, partnership agreements, or significant corporate changes as they occur.
For clinical-stage biotech companies like Biomea Fusion, the Management's Discussion and Analysis sections in 10-K and 10-Q filings are particularly valuable. These sections explain the company's clinical development strategy, trial timelines, regulatory pathway, and management's assessment of capital requirements. The Risk Factors section outlines potential challenges including clinical trial failures, regulatory setbacks, competitive threats, and financial risks. Proxy statements (DEF 14A) reveal executive compensation, board composition, and governance matters.
Registration statements and prospectuses related to equity offerings detail the terms of capital raises and dilution to existing shareholders. Investors tracking BMEA should monitor filings for updates on clinical trial progress, changes in cash position, partnership developments, and any modifications to the company's development priorities. This comprehensive filing archive enables investors to access the primary source documents that drive investment decisions in BMEA stock.
Rainer M. Erdtmann, a director and officer of Biomea Fusion (BMEA), reported multiple late-January 2025 stock transfers and a large option award. On 01/28/2025 he disposed of 40,000 shares and on 01/31/2025 recorded three additional disposals of 10,000 each alongside three indirect acquisitions of 10,000 shares attributed to his children, leaving 643,027 shares held directly following those transactions.
The filing discloses indirect holdings held in Trust 1 (174,614), Trust 2 (1,134,989), Point Sur Investors Fund I, LP (228,470) and Point Sur Investors, LLC (252,320). It also reports a grant of 1,246,989 stock options on 08/11/2025 with a $1.53 exercise price, vesting in 16 quarterly installments beginning 08/08/2025 and fully vesting 08/08/2029, expiring 08/10/2035.
Blue Owl Capital Holdings LP reports beneficial ownership of 3,800,000 shares of Biomea Fusion common stock, representing 6.13% of the outstanding class. The position is composed of 1,300,000 directly held shares and 2,500,000 shares issuable upon exercise of warrants. The filing states the percentage was calculated using the issuer's reported outstanding share count plus the warrants. The reporting person discloses shared voting and shared dispositive power over the reported shares and confirms the securities are held in the ordinary course of business and not to influence control.
CVI Investments and Heights Capital Management have reported a significant stake in Biomea Fusion, collectively holding 5,834,871 shares representing 9.9% of the company's common stock. The position consists of 4,450,000 direct shares and additional shares issuable through pre-funded warrants and other warrants.
Key details of the filing include:
- Heights Capital Management serves as the investment manager to CVI Investments and can exercise voting and dispositive power over the shares
- The warrants contain a 9.99% beneficial ownership limitation clause
- CVI Investments is based in the Cayman Islands, while Heights Capital Management is incorporated in Delaware
- Both entities have shared voting and dispositive power over all reported shares, with no sole voting or dispositive power
The filing certifies that the securities were not acquired to influence control of Biomea Fusion or in connection with any transaction having such purpose. The stake was reported following a recent offering referenced in the company's June 18, 2025 Prospectus Supplement.
FAQ
What is the current stock price of Biomea Fusion (BMEA)?
What is the market cap of Biomea Fusion (BMEA)?
